Consumer Health (OTC) Products; U.S. > Add the event to my calendar, Cowens 43rd Annual Health Care Conference The Board will review any alternative options for the consumer healthcare unit and compare them with shareholders opportunity cost, including taxes and other expenses. 12% in EUROAPI shares from Sanofi for up to 150 million, with the acquisition price to be determined based upon the thirty day volume weighted average trading price (VWAP) of EUROAPIs shares on Euronext Paris, starting on the first day of trading. Physical and Mental Wellness. investor.relations@sanofi.com, France:+ 33 1 53 77 45 45 |U.S.:+ 1 908 981 5560. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Low Back Pain (LBP) continues to be the leading reason for Years Lost to Disability (YLTD) in every region of the world,4 affecting around 1 in 10 people. Again, the sooner the better. JUNE 28, 2021. Our mission is to Serve Healthier, Fuller Lives by offering moments of relief to our Patients & Consumers in our key platforms, including Allergy, Physical & Mental Wellness, Pain . If you wish to continue to this external website, click Proceed. All rights reserved. Please disable your ad-blocker and refresh. Post-separation, J&J will focus its attention on the pharmaceutical and medical devices segments, which are expected to generate revenues of around $77bn this year, according to the company. In financial year 2020, STADA achieved group sales of EUR 3,010.3 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 713.3 million. Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA. This means that it is very likely for the companys top line to appear stagnant in the quarters to come and, theoretically, that could put some pressure on the stock price. I have no business relationship with any company whose stock is mentioned in this article. Post separation, the new Consumer Healthcare company is expected be listed on London Stock Exchange (LSE) with ADR to be listed in the US. If you wish to continue to this external website, click Proceed. "Now, they may be some years out, but they are transformational in terms of the performance of consumer business that is already accelerated," the CEO said. Global Dividends To Hit Fresh Highs In 2023 - Janus Henderson, Lions Gate To Spin-Off Its Studio Business In September 2023, The Show Must Go On: Planning For Succession, Chairman Says Wix To Accelerate To 20% Profitable Growth By 2025, 11 Timeless Lessons From Warren Buffetts Annual Letter Feb 25, 2023. The company's consumer healthcare unit, a maker of over-the-counter drugs (OTC), lifted sales by 9.1% to 1.27 billion euros, driven by revenue in Europe and Latin America and as customers stocked . Opinions expressed by Forbes Contributors are their own. Elsewhere, Sanofi said it expects trials of the COVID-19 shot being developed in conjunction with GSK to read out later this quarter, while a late-stage vaccine for respiratory syncytial virus developed with British COVID-19 vaccine-maker AstraZeneca PLC is expected to be filed with regulators this year. If you have an ad-blocker enabled you may be blocked from proceeding. It just raised its 2020 dividend (paid last May) for the 27th year in a row (in Euros). Therefore, their poor performance affects the overall results: General Medicines declined by 9% and Consumer Healthcare by 14% YoY. On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed . We believe the deteriorating performance at the largest segment may have triggered the need to refocus on the biopharma business. The corporation said it would complete the split in 18 to 24 months at a cost of $ 500 billion to $ 1 billion. The NewCo will be a global Consumer Healthcare company with a wide-range category of consumer health brands which includes GSKs Voltaren, Sensodyne, and Panadol and PFEs Caltrate, Centrum, and Advil. J.P. Morgan & Cie S.A.S. Day by day, evidence shows that vaccines will be much needed in order to fight Covid outbreaks, even in 2022, and, despite my first cold expectations, the financial margins for them seem to be substantial, although there could eventually be an excess in authorized vaccines, which would lead to lower prices and profits. With this focused attention from management, the consumer-health spin-off enjoyed a relatively smooth path to independence and a successful public listing. Sanofi Offloads 16 Consumer Health Brands Health 9 hours ago Web As part of its quest to streamline consumer healthcareand eventually spin off the unit as a standalone businessSanofi will offload 16 consumer . Sanofi's fourth quarter saw consumer health sales rise 5.6%, driven . Sanofi assumes no responsibility for the information presented on this website. We understand allergy sufferers needs and have a number of innovative, effective products in our range to respond effectively to each persons specific allergy needs. Sanofi's CDMO spinoff set for next month as new group targets 2022 revenues of 1B. 2021 position: 2. Julie Van Ongevalle The company intends to structure the transaction in a tax efficient manner for both the UK and US shareholders, subject to confirmation from the relevant tax authorities. You may opt-out by. It was the world's second largest manufacturer of APIs (including both small and large molecules such as peptides and oligonucleotides) in 2021 and number seven in the global CDMO (Contract Development and Manufacturing Organization) market in 20201. Start Now! "Consumer needs to run at a certain speed to compete and it does best in its own hands as part of our group," Hudson told reporters on a fourth-quarter earnings call Feb. 4. Total Pharmaceuticals reported 6.434 billion, Sanofi Pasteur (Vaccines) reported 1.929 billion. French Tech Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other customary conditions. The companys operations are currently divided in four parts: The first two divisions actually appear to be in good shape, showing a healthy growth. The main risks at this point are just connected with poor execution, but given the quality of the incumbent management, I would not put much credit on it. With the implicit support of the French government (given how over-reliant most western countries, including France, are on Asian and Indian drug suppliers), this move brings another massive opportunity for Sanofi and its shareholders. The leading site for news and procurement in the pharmaceutical industry. The split, J&J said, would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers. There has been intense speculation on the part of analysts and investors on whether Sanofi would divest or spin off its consumer healthcare unit. The French pharma giant first announced its intentions to spin off the API business in February.The plan, as the company said at the time, would combine Sanofi's API . At its third-quarter financial report on October 31, Sanofi reported total net sales of 9.499 billion for the quarter, with Consumer Healthcare reporting 1.136 billion, up 0.4%. According to news reports, in April 2021, activist investment firm Elliott Management Corp. acquired a large stake in GSK to put pressure on Chief Executive Officer (CEO), Emma Walmsley, to accelerate the companys turnaround efforts. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. The gut is often referred to as the bodys second brain. Credit Suisse London Health Care Conference The move by the world's largest health products company follows similar announcements by conglomerates Toshiba General Electric, as well as J&J rivals, and underscores how big . The Consumer Healthcare unit had two major deals in 2018, when GSK acquired Novartis' 36.5% stake in its consumer healthcare joint venture (JV) followed by a merger with Pfizer's consumer healthcare business into a JV. The joint venture has a global market share of 3.5%. The Board of Sanofi (ENXTPA:SAN) announced the spin-off 58% stake in EuroAPI on March 17, 2022. The combined global sales were about $12.7 billion in 2017. Final note: I am long Sanofi directly through its shares listed in Europe. GSK cited the opportunity cost from the immense profit and cash generation potential of the consumer healthcare unit as well as higher expenses in the form of taxes in case of a sale as compelling reasons for the spin-off. Any material effect of COVID-19 or recent armed conflicts on any of the foregoing could also adversely impact us. How management will address them we dont know of course, but here are some likely solutions they may put in place in a relative short time which will act as strong catalysts for Sanofis business. Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. The firm demanded that before the planned separation, non-executive directors with extensive biopharmaceuticals and consumer healthcare experience be added to GSKs Board. Additionally, the oncology division is experiencing a strong momentum, with Sarclisa and Libtayo bringing a 25% growth rate. With a diversified technology portfolio, EUROAPI is positioned as the world's leading manufacturer of small molecule API (including complex chemical synthesis molecules, biochemical molecules from fermentation and highly potent molecules). Business is on track to demerge and list as a new company in mid-2022. 75017 Paris FRANCE At the time, Hudson stated, Since joining Sanofi only two months ago, I am increasingly excited about the strength of our businesses, our ability to develop transformative medicines and the diverse talent of our teams across the organization. Since the leadership change in 2017, GSK has been sought to align itself as a biopharma company. Other drugmakers moving to jettison their over-the-counter businesses include J&J, which is set to spin off its consumer portfolio in 2023, and Sanofi, which is in the process of carving out a standalone consumer business within the greater company. Our brands are trusted across the world, and some have been on the market for over 50 years. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. Self-care can enhance wellbeing, prevent disease, curb illness, and restore health. The financial leverage is quite low too, which is a positive sign for the strength of the balance sheet and it could boost Sanofis M&A activity in the years to come, which is always an important option for big pharma companies. For July 2022 GlaxoSmithKline [GSK.L] set the scene for one of the biggest listings in . Across the world, 77% of people have used nutritionals in the last 12 months to maintain their general health, provide immune system support or to supplement in areas of vitamin deficiency. Our high-quality products are available in more than 5,780 pharmacies. The digestive system provides energy and fuel for the whole body, so when someone suffers from gastro intestinal disorders, their life can literally be put on hold. (2021). In 2018, Pfizer split itself into three business units after failing to sell off its consumer health segment. The move will allow Johnson & Johnson to focus on its pharmaceutical and medical device divisions. J & J stocks, which are a portion of the Dow Jones Manufacturing Average (.DJI), rose 1.5%. Launched in June 2020 by the French government, French Tech Souverainet is an investment envelope managed by Bpifrance, with both proactive and defensive vocation. The company was formed by a merger between Glaxo Wellcome plc and SmithKline Beecham plc. However, it looks like that les grandes manoeuvres, aimed at the realization of this project, will proceed at a slow speed. Sanofi moves forward with EUROAPI listing on Euronext Paris. Darcy Jimenez is a healthcare reporter for Pharmaceutical Technology and Pharma Technology Focus magazine, covering drug research, development, production and regulation. Paul Hudson, Sanofis chief executive officer, who took over the reins of the company on September 1, is expected to meet with investors in Cambridge, Massachusetts on December 10. The deal increased Sanofis consumer healthcare market share to about 4.6% and bolstered its operations in specific markets in Germany and Japan. Incorporated in 1999, GlaxoSmithKline plc (GSK), a British company based in United Kingdom. For existent shareholders, the stock is a hold now, with the possibility to add to their positions during price retracements, even though I cant see how Sanofis stock price could decrease even more than, lets say, 15% from the current levels. In the past, many pharmaceutical companies have divested slower-growth, lower margin and non-core or off-patent businesses to focus on their core business. All in all, even though the stagnant divisions are at the moment predominant, that story is changing. On June 23, 2021, GlaxoSmithKline plc (NYSE: GSK, $40.45, Market Cap: $101.8 billion) announced that it plans to spin-off its Consumer Healthcare division into a separately listed company. Morningstar analyst Damien Conover said: The firms timing is surprising, as we dont see any major catalyst for the move. I am not receiving compensation for it (other than from Seeking Alpha). GSK's consumer health spinoff Haleon will make its big debut in just over a week but with some serious debt in tow, according to the company. In addition to the previously proposed 3.33 cash dividend per Sanofi share, this additional extraordinary dividend, exclusively in kind, is subject to shareholders approval GlaxoSmithKline and Pfizer plan to spin off their joint consumer health business next year, and German drugmaker Merck KGaA sold its consumer health division to Procter & Gamble Co in 2018. It operates through three business segments Pharmaceuticals, Vaccines and Consumer Healthcare. This, in turn, will contribute significantly to more sustainable healthcare systems. It will lead to the creation of a consumer health giant with a market share of 7.3 percent, well ahead of its nearest rivals Johnson & Johnson, Bayer and Sanofi, all on around 4 percent. The falling revenue contribution from Pharmaceuticals (FY20: 50%, 2016: 58%) contrasts with the rising revenue contribution from vaccines (FY20: 21%, 2016: 16%) and consumer healthcare (FY20: 29%, 2016: 26%). It is provided for information only. As of 31 December 2020, STADA employed 12,301 people worldwide. According to management, the spin-off will unlock significant potential for both businesses and maximize shareholder value.

Lobster Bisque Recipe Rick Stein, Articles S